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Abstract
Background: Novel pro-inflammatory and anti-inflammatory derivatives from adipose tissue, known as adipokines,
act as metabolic factors. The aim of this study was to analyse the secreted expression of different adipo/cytokines
in secretomes of unstable carotid atherosclerotic plaque versus non-atherosclerotic mammary artery.
Methods: We evaluated the secretion levels of adiponectin, visfatin, lipocalin-2, resistin, IL-6 and TNFR2 by ELISA in
human secretomes from cultured unstable carotid atherosclerotic plaque (n = 18) and non-atherosclerotic mammary
artery (n = 13). We also measured visfatin serum levels in patients suffering from atherosclerosis and in a serum cohort
of healthy subjects (n = 16).
Results: We found that visfatin levels were significantly increased in unstable carotid atherosclerotic plaque
secretome than in non-atherosclerotic mammary artery secretome. No differences were found with regard the
other adipo/cytokines studied. Regarding visfatin circulating levels, there were no differences between unstable
carotid atherosclerotic plaque and non-atherosclerotic mammary artery group. However, these visfatin levels were
increased in comparison to serum cohort of healthy subjects.
Conclusions: Of all the adipo/cytokines analysed, only visfatin showed increased levels in secretomes of unstable
carotid atherosclerotic plaque. Additional human studies are needed to clarify the possible role of visfatin as
prognostic factor of unstable carotid atherosclerotic plaque.
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Background
Carotid artery stenosis as a causative factor of ischemic
strokes or transient ischemic attacks constitutes a major
therapeutic target. Since obesity is considered a risk factor
associated to atherosclerosis, a lot of research over recent
years has tried to gain greater insights into the link
between atherosclerosis and adipose tissue that has been
described as an endocrine organ that secretes a wide
variety of proteins called adipokines [1–3]. Currently, it is
well known that adipokines play a relevant role in the
pathophysiology of cardiovascular diseases (CVDs) [4–6].
These molecules can act as enzymes, hormones or growth
factors in the modulation of insulin resistance and the
metabolism of fats and glucose, and, therefore, have an
indirect effect on atherosclerosis [7]. To note, visceral
fat accumulation associated with adipokine dysregulation
affects on both atherosclerotic plaque development and
plaque disruption. When the advanced plaque becomes
unstable, rupture can occur and may be provided by the
adipokine-induced prothrombotic and inflammatory state
[8, 9]. During the last century, the epidemic of obesity and
CVDs has lead to intense research into the role of adipo-
kines in obesity and atherosclerosis [6]. However, further
research is necessary to elucidate more thoroughly the
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pathophysiological pathways that underlie the association
between adipokines and atherosclerosis, and their poten-
tial role as new therapeutic approaches and biomarkers.
Recently, the study of the secretome has emerged as
a new strategy for analysing the formation of athero-
sclerotic plaques in humans [10]. The secretome is the
sub-set of proteins released by a cell or tissue under
certain conditions and shows a narrower dynamic
range of proteins than serum or plasma, which means
less complexity. Furthermore, studies on tissue secre-
tome more closely resemble the in vivo situation than
cell culture workflows.
The aim of this study was to analyse the presence of
several adipo/cytokines with different profiles, pro- and
anti-inflammatory: adiponectin, visfatin, lipocalin-2,
resistin, IL-6 and TNFR2, and compare their differential
expression in the secretome of an unstable carotid
atherosclerotic plaque with the secretome in a non-
atherosclerotic mammary artery. Moreover, in order to
study whether the differences observed in adipo/cytokine
levels were only a local effect or if they were also reflected
in serum, we measured circulating levels in the group of
patients suffering from atherosclerosis and in a serum
group of healthy subjects.
Methods
Subjects/Samples
The study was approved by the institutional review
board “Comitè d’Ètica d’Investigació Clínica, Hospital
Universitari de Sant Joan de Reus” (10-04-29/4proj3). All
participants gave written informed consent for participa-
tion in medical research.
Human unstable carotid atherosclerotic plaques were
obtained from patients (men, n = 18) who underwent
carotid endarterectomy at the Angiology and Vascular
Surgery Unit of the Hospital Universitari Joan XXIII
(Tarragona, Spain). Patients with cerebrovascular ische-
mia and internal carotid artery stenosis >75 % were in-
cluded, diagnosed by colour Doppler assisted duplex
investigation and arteriography. The diagnosis of un-
stable carotid atherosclerotic plaques was made by an
experienced pathologist following the American Heart
Association (AHA) guidelines [11].
Mammary arteries were used as non-atherosclerotic
control arteries. Segments of mammary arteries (men,
n = 13) were obtained during coronary revascularisation
surgery at the Cardiovascular Surgery Department of the
Hospital Germans Trias i Pujol (Badalona, Spain). Patients
who had an acute illness, acute or chronic inflammatory
or infective diseases, or malignant neoplastic disease were
excluded.
We also recruited serum cohort of healthy men (n = 16),
whose medical history included no cardiovascular event.
Subjects who had an acute illness, acute or chronic
inflammatory or infective diseases, or malignant neoplas-
tic disease were excluded.
All subjects recruited were male. Blood samples were
obtained from each individual immediately before sur-
gery and after overnight fasting. Serum was obtained by
standard protocols and preserved at −80 °C until use.
Clinical and biochemical assessments
A complete anthropometric, biochemical, and physical
examination was carried out on each patient. Body
height and weight were measured with the patient stand-
ing in light clothes and shoeless. Body mass index (BMI)
was calculated as body weight divided by height squared
(kg/m2). Laboratory studies included glucose, insulin,
glycated haemoglobin (HbA1c), total cholesterol, high-
density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C) and triglycerides, all of
which were analysed using a conventional automated
analyser. Insulin resistance (IR) was estimated using the
homeostatic model assessment of IR (HOMA2-IR) [12].
Arterial tissue culture – obtaining the secretome
Tissue samples were transported from the surgery to the
laboratory in phosphate buffered saline (PBS) at room
temperature. Immediately upon arrival, the tissue was
transferred to a Petri dish and washed with PBS. For
mammary arteries, we removed the adventitia before in-
cubation of the intima-media. All samples were then cut
into similar-sized pieces about 3–5 mm in length and
transferred to a 12-well tissue culture plate containing
2 ml/well of protein-free Roswell Park Memorial Institute
medium (RPMI) (RPMI-1640, Gibco, Invitrogen, N.Y,
USA) supplemented with penicillin (100 U/ml), strepto-
mycin (100 μg/ml) and 50 mM HEPES. These procedures
were all carried out under a laminar flow hood using ste-
rile equipment. After 24 h of incubation at 37 °C and 5 %
of CO2, the media containing the secreted proteins, the
so-called secretome, were collected, aliquoted and stored
at −80 °C until used for analysis.
Additionally, a section of each atherosclerotic plaque
was placed in phormol 10 % and further studied by an
experienced pathologist from the Hospital Universitari
Joan XXIII (Tarragona) following the AHA guidelines [11].
Measurements of adipo/cytokines levels
Defrosted secretome samples were centrifuged at 1200
rpm and 4 °C for 15 min. Then, they were analysed by
enzyme-linked immunosorbent assays (ELISA) following
the manufacturer’s instructions. Adiponectin (EMD
Millipore, St. Charles, MI, USA), visfatin (AdipoGen,
San Diego, CA, USA), lipocalin-2 (R&D Systems Inc,
Minneapolis, USA), resistin (Biovendor, Modrice, Czech
Republic), IL-6 (R&D Systems Inc, Minneapolis, USA)
and TNFR2 (BioSource Europe, Nivelles, Belgium) were
Auguet et al. BMC Cardiovascular Disorders  (2016) 16:149 Page 2 of 7
determined in secretome samples. Only visfatin was de-
termined in both secretome and serum samples. The
adiponectin assay sensitivity was 0.2 ng/ml, and intra-
assay and inter-assay coefficients of variation (CV) were
3.4 and 5.7, respectively. The visfatin assay sensitivity
was 30 pg/ml, and intra-assay and inter-assay CV were
5.63 and 5.92, respectively. The lipocalin-2 assay sensi-
tivity was 0.012 ng/ml, and intra-assay and inter-assay
CV were 3.7 and 6.5, respectively. The resistin assay sen-
sitivity was 0.012 ng/ml, and intra-assay and inter-assay
CV were 5.9 and 7.6, respectively. The IL-6 assay sensi-
tivity was 0.039 pg/mL, and intra-assay and inter-assay
CV were 7.4 and 7.8, respectively. Finally, sTNF-RII
assay sensitivity was 0.1 ng/ml, and intra-assay and
inter-assay CV were 4.9 and 7.9, respectively. In order to
normalize adipo/cytokine measurements, total protein
concentration was assessed using the Pierce BCA pro-
tein assay kit (Thermo Scientific, Waltham, MA, USA)
following the manufacturer’s instructions.
Statistical analysis
All the values reported are expressed as mean ± standard
deviation (SD) and were analysed using the Windows
SPSS/PC+ statistical package (version 22.0; SPSS,
Chicago, IL, USA). Differences between groups were
calculated using Student’s t test or one-way ANOVA
analysis. The strength of association between variables
was calculated using Pearson’s method for parametric
variables and the Spearman Rho correlation test for
non-parametric contrasts. P values <0.05 were consid-
ered to be statistically significant.
Results
Characteristics of the population studied
The general characteristics and biochemical measure-
ments of the population studied are shown in Table 1.
Subjects were classified according to the samples ob-
tained: serum group of healthy subjects (n = 16), non-
atherosclerotic mammary artery samples from patients
undergoing coronary artery bypass (n = 13) and un-
stable carotid atherosclerotic plaque samples from pa-
tients undergoing endarterectomy (n = 18). The three
groups studied had similar BMIs and they were all
men. Anthropometrical and biochemical parameters
showed no significant differences between non-
atherosclerotic mammary artery and unstable carotid
atherosclerotic plaque groups. As expected, carotid
atherosclerotic plaque and mammary artery patients
showed significant lower lipid profile because these
subjects were taking lipid-lowering drugs. Table 1 also
shows that the levels of glucose and HbA1c were sig-
nificantly higher in the carotid atherosclerotic plaque
and mammary artery group than in serum group of
healthy subjects.
Adipo/cytokine levels in the secretome
To study the local role of adipo/cytokines in atheroscler-
osis, we evaluated the presence of adiponectin, visfatin,
lipocalin-2, resistin, IL-6 and TNFR2 in secretomes of
the unstable carotid atherosclerotic plaque and non-
atherosclerotic mammary artery tissue cultures (Table 2).
Of all the molecules analysed, visfatin was the only adipo/
cytokine that was differently expressed in secretome
Table 1 Anthropometric measurements and metabolic analysis










(n = 16) (n = 13) (n = 18)
Mean ± SD Mean ± SD Mean ± SD
Age (years) 52.47 ± 13.25 65.08 ± 10.48 69.17 ± 7.44b
BMI (kg/m2) 32.19 ± 11.76 29.39 ± 3.36 27.74 ± 3.13
Glucose (mg/dl) 91.31 ± 14.24 129.19 ± 55.44a 123.56 ± 45.37b
HbA1c (%) 4.97 ± 0.39 6.81 ± 1.39a 6.29 ± 1.07b
Insulin (mUI/L) 12.76 ± 16.19 11.76 ± 7.15 7.21 ± 4.93
HOMA2-IR 1.62 ± 1.95 1.59 ± 0.97 1.01 ± 0.67
Triglycerides (mg/dL) 115.02 ± 71.38 110.33 ± 27.84 103.00 ± 40.61
Cholesterol (mg/dl) 192.33 ± 37.81 128.34 ± 23.92a 118.81 ± 34.54b
HDL-C (mg/dL) 49.13 ± 10.35 23.71 ± 4.64a 28.50 ± 6.98b
LDL-C (mg/dL) 120.17 ± 39.06 78.56 ± 19.48a 69.78 ± 26.21b
Subjects were classified according to the samples obtained: serum group of
healthy subjects (n = 16), non-atherosclerotic mammary artery samples from
patients undergoing coronary artery bypass (n = 13) and unstable carotid
atherosclerotic plaque samples from patients undergoing endarterectomy
(n = 18). BMI body mass index, HbA1c glycosylated haemoglobin, HOMA2-IR
homeostatic model assessment 2- insulin resistance, HDL-C high density
lipoprotein, LDL-C low density lipoprotein. Data are expressed as mean ± SD.
p <0.05 are considered statistically significant. arefer to the statistically significant
differences between coronary patients with non-atherosclerotic mammary artery
and serum group of healthy subjects. brefer to the statistically significant
differences between unstable carotid plaque and serum group of healthy
subjects. HOMA-2 is calculated using the HOMA Calculator version
2.2.2 (http://www.dtu.ox.ac.uk)







(n = 18) (n = 13)
Mean ± SD Mean ± SD
Visfatin (ng/μg total protein) 0.100 ± 0.017 0.046 ± 0.012a
Adiponectin (μg/μg total protein) 0.311 ± 0.039 0.369 ± 0.096
IL-6 (pg/μg total protein) 0.048 ± 0.012 0.039 ± 0.008
Lipocalin-2 (ng/μg total protein) 0.009 ± 0.002 0.008 ± 0.001
Resistin (ng/μg total protein) 0.001 ± 0.001 0.001 ± 0.001
TNFR2 (ng/μg total protein) 0.007 ± 0.002 0.005 ± 0.001
IL-6 interleukin 6, TNFR2 tumor necrosis factor receptor 2. Data are expressed
as mean ± SD. p <0.05 are considered statistically significant. arefer to the
statistically significant differences between unstable carotid atherosclerotic
plaque and non-atherosclerotic mammary artery group
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samples. Specifically, visfatin levels were significantly
higher in the unstable carotid atherosclerotic plaque than
in non-atherosclerotic mammary artery secretomes
(Table 2, p = 0.021). Conversely, the levels of adiponectin
and IL-6 showed no significant differences between the
two secretome groups analysed. Finally, the levels of
lipocalin-2, resistin and TNFR2 were almost undetectable
in the secretome samples. No significant correlations be-
tween adipo/cytokines were found.
Circulating Visfatin and adipocytokines levels in serum
As only differences in situ visfatin levels were observed
and in order to study whether these differences were
only a local effect or if they were also reflected in serum,
we measured visfatin circulating levels in the group of pa-
tients suffering from atherosclerosis and in a serum group
of healthy subjects (n = 16). Fig. 1 shows that there were
no differences between unstable carotid atherosclerotic
plaque and non-atherosclerotic mammary artery group.
However, visfatin serum concentration was higher in
both unstable carotid atherosclerotic plaque and non-
atherosclerotic mammary artery groups than in the
serum cohort of healthy subjects (p = 0.037 and p = 0.001;
respectively). This difference remained significant after
adjusting for age, BMI and glucose metabolism.
Then, we analysed the circulating levels of two adipo/
cytokines with different profile, pro- and anti-inflammatory
(IL-6 and adiponectin, respectively). We found that adipo-
nectin circulating levels were significantly higher in the
serum group of healthy subjects (29.20 ± 8.42) than
unstable carotid atherosclerotic plaque group (11.23 ± 1.69,
p = 0.025) and non-atherosclerotic mammary artery pa-
tients (9.26 ± 2.35, p = 0.031). However, we observed no
differences in the circulating levels of IL-6 between groups.
No significant correlations between these adipo/cytokines
and visfatin were found.
Discussion
To date, the knowledge of the local action of the adipo/
cytokines expressed in secretomes of atherosclerotic pla-
ques is under development. In fact, most secretome
studies have been carried out using proteomic tech-
niques [10, 13]. The aim of this study was to analyse the
presence of several adipo/cytokines with different pro-
files, pro- and anti-inflammatory in the secretome of an
unstable carotid atherosclerotic plaque with the secre-
tome in a non-atherosclerotic mammary artery. The
main finding was that visfatin levels were significantly
higher in the unstable carotid atherosclerotic plaque
than in non-atherosclerotic mammary artery secretomes,
suggesting a possible link between visfatin and unstable
carotid atherosclerotic plaque.
Visfatin is a ubiquitous adipokine that is produced in
adipose tissue, bone marrow, skeletal muscle, and liver
with a physiological role not completely understood
[14–16]. In the context of metabolic diseases, most stud-
ies have focused on increased circulating levels and adi-
pose tissue expression of visfatin [17, 18]. Also, it was
initially proposed as a clinical marker of atherosclerosis,
endothelial dysfunction and vascular damage [19]. Also,
Fig. 1 Visfatin serum levels in different groups: unstable carotid atherosclerotic plaque group (n = 18), coronary patients with non-atherosclerotic
mammary artery (n = 13) and serum cohort of healthy subjects (n = 16). p <0.05 were considered statistically significant
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visfatin is an active player promoting vascular inflamma-
tion, atherosclerosis development and progression, and
plaque destabilization [19–21]. As far as the local effect
of visfatin on atherosclerotic lesions is concerned, other
authors studying the atheroma plaque directly have re-
ported similar results to ours [22–24]. One of the studies
that has most similarities with ours has reported that
visfatin should be regarded as an inflammatory mediator,
localized to foam cell macrophages within unstable ath-
erosclerotic lesions, which potentially plays a role in
plaque destabilization [22]. Moreover, Zhou et al. have
reported that visfatin induces cholesterol accumulation
in macrophages and accelerates the process of athero-
sclerosis [23]. Apart from the pro-inflammatory effect of
visfatin on atherosclerosis, other possible direct mecha-
nisms have been reported: promotion of smooth muscle
cell proliferation, alteration of the expression and the
activity of matrix metalloproteinases, greater atheroscler-
otic plaque vulnerability and impairment of endothelial
vasodilatory responses [25–28]. The mechanism under-
lying elevated levels of visfatin in secretomes from un-
stable atherosclerotic plaques are not known nowadays.
However, Dahl et al. have reported enhanced visfatin
expression in symptomatic atherosclerotic plaques and
also that visfatin had a combined ability of increasing
TNF-α as well as to respond with increased expression
on TNF-α stimulation. Therefore, this bidirectional
interaction between TNF-α and visfatin could represent
a pathogenic loop on unstable atherosclerotic lesions [22].
Another study has further demonstrated that the regulation
of visfatin in macrophages is related to pro-atherogenic
stimuli, including hypoxia, TNF-α and ox-LDL [29].
Although some authors have identified that visfatin is a
potential inflammatory mediator in plaque destabilization
[22], in our study we only included patients with cerebro-
vascular ischemia and unstable carotid atherosclerotic
plaque. Therefore, we could not compare visfatin levels
between stable and unstable carotid plaque secretomes.
Although the biological mechanisms involving visfatin
in the pathogenesis of atherosclerosis are not well-
established, visfatin seems to be an active factor in the
development and progression of atherosclerosis through
its effects on cytokine and chemokine secretion, macro-
phage survival, leukocyte recruitment by endothelial
cells, vascular smooth muscle inflammation and plaque
destabilization [19, 23].
Regarding circulating levels, we found higher visfatin
serum concentrations in patients suffering carotid athero-
sclerosis and coronary patients with non-atherosclerosis
mammary artery who underwent coronary revascularisa-
tion surgery. In our study, mammary arteries have been
used as control arteries, since previous studies have shown
its lower incidence of atherosclerosis [30, 31]. However, it
is important to remark that although mammary artery
patients have non-diseased arterial secretome, they have
atherosclerotic coronary disease. Likewise, in recent years,
several studies have established positive associations be-
tween enhanced circulating visfatin levels and atherogenic
inflammatory diseases, which suggest a possible role of
visfatin in the atherosclerosis pathogenesis [19, 32]. Speci-
fically, visfatin was associated with infarct-related artery
occlusion, and also an association with coronary artery
disease was found [33, 34]. On the other hand, some au-
thors claim that high visfatin levels, instead of depicting
changes in the atherosclerotic process are more likely to
reflect changes in systemic inflammation in patients with
cardiovascular disease [19]. Although our local and sys-
temic results reinforce the first hypothesis, additional hu-
man studies are needed if these data are to be clarified.
Regarding the other adipo/cytokines, levels of lipocalin-
2, resistin and TNFR2 were almost undetectable in the
secretome samples. In addition, the levels of adiponectin
and IL-6 showed no differences between the two secre-
tome groups analysed. Several studies have described a
protective role of adiponectin in cardiovascular diseases
[35]. Although we did not find differences between secre-
tome groups, we found higher serum levels of adiponectin
in control individuals than in both unstable carotid
atherosclerosis and non-atherosclerotic mammary artery
patients. Further studies are needed to assess whether adi-
ponectin can have a direct effect in situ by inhibiting the
formation of an atherosclerotic plaque. Although IL-6 has
been regarded as a pro-inflammatory cytokine that is clas-
sically associated with endothelial dysfunction and athero-
sclerosis [36], we found no differences in secretome or
circulating levels between the group of patients suffering
from atherosclerosis and the mammary artery. The reason
for these discrepancies could be the dissimilarities of the
studied populations.
Our results require the following observations. First,
we have used mammary arteries as control arteries, since
previous studies have shown a lower incidence of athero-
sclerosis. However, non-atherosclerotic carotid arteries
would be the best choice but, unfortunately, are not avai-
lable. Second, this study was cross-sectional, so it allowed
us to detect correlations but not to formulate predictions.
Future prospective studies are necessary to elucidate more
thoroughly the association between some molecules such
as visfatin and atherosclerosis, and also their potential role
as new therapeutic approaches and biomarkers of unstable
vs. stable plaques. As our study was conducted only in-
cluding unstable plaques, we could only suggest doing
further in order to confirm this hypothesis.
Conclusions
Of all the adipo/cytokines analysed in secretomes, visfa-
tin was the only adipo/cytokine that was higher in un-
stable carotid artery plaque than in non-atherosclerotic
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mammary artery secretomes. Regarding visfatin serum
levels, there were no differences between unstable
carotid atherosclerotic plaque and non-atherosclerotic
mammary artery groups. However, these visfatin cir-
culating levels were increased in comparison to serum
cohort of healthy subjects. Prospective studies are
needed to confirm whether visfatin could play a role
as prognostic factor in the stability of atherosclerotic
plaque.
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